MannKind Corp, the Valencia manufacturer of inhaled insulin drug Afrezza, reportedly is exploring strategic options, including the possible sale of itself, according to Reuters. MannKind has not commented on the report.
Earlier this month France's Sanofi terminated its agreement to sell Afrezza for MannKind after poor sales. Mannkind’s stock dropped 40 percent.
Since then, MannKind has started developing a new marketing and sales strategy and has pursued other partnerships. It also brought on a new chief executive, Matthew Pfeffer, to replace Alfred Mann, who remains chairman.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Air Goes Out of Inhalable Insulin on Wall Street
- Afrezza Now Available in U.S.
- MannKind in Talks for Afrezza Partnership
- MannKind Shares Plunge With End of Sanofi Deal
- MannKind Gets FDA Approval for Inhalable Insulin
- FDA Delays Afrezza Decision
- MannKind Reaches Deal to Sell Inhaled Insulin
- FDA Could Limit MannKind Inhaler